Skip to main content
Skip to main navigation
Search for :
Product Development Strategy
Early Clinical Development
Phase I/IIa Clinical Trials
Phase II/III Clinical Trials
Interventional Phase IIIb/Phase IV Clinical Trials
Observational Research & Registries
Product Launch & Management
Market Access Solutions
Strategic Sales Outsourcing
Biopharmaceutical Sales & Marketing
Healthcare Payers & Providers
Medical Device & Diagnostics
Public Health & Government
Small to Mid-Sized Biopharma
Specialty Clinical Associations and Patient Organizations
Central Nervous System
Diabetes & Endocrinology
Early Phase Oncology
Public Health Interest
Other Therapeutic Areas
Ethics & Compliance
Determining the right approach for the right question
How can you satisfy the varying demands of regulators, payers, physicians and patients? Trust Quintiles to help optimize your real-world and late phase research.
Outsourcing in a Changing Environment
Head of US Commercial operations at Quintiles, Daryl Gaugler, presented ways to build strategic value by going beyond tactical commercial outsourcing.
A Blueprint for Clinical / Commercial Convergence
Bio pharmaceutical companies must shift from two divergent paths to one that combines clinical and commercial resources.
Read white paper
Before or after your product passes regulatory approval, real-world and late phase research can help you maximize your asset’s value.
Interventional late phase trials require more agility when your market window is closing.
Give payers evidence of real-world effectiveness to gain faster reimbursement.
Find out how
Now together for you – the leader in interventional late phase trials and the leader in observational research.
Quintiles Recognized as Industry Leader in Phase II/III Research for Second Year in a Row
Quintiles’ First Quarter 2014 Earnings Call Scheduled for Thursday, May 1st
Quintiles Appoints Dr. Stella Blackburn to Lead Global Risk Management
The Collaboration Mandate
Partnerships, Patients and Proof
Biomarkers: Recent Advances in their Application to the Treatment of Hematologic Malignancies